Friday, 22 Mar 2019

You are here

Allopurinol Dose Escalation is Safe with Severe CKD

Hypertension, nephrolithiasis and chronic kidney disease (CKD) commonly associates with gout.  While there is a clear need to dose adjust NSAIDs and colchicine in those with CKD, there is some debate about the need to dose adjust when using allopurinol with CKD.

Stamp and coworkers from Auckland did a post-hoc analysis of a 24-month allopurinol dose escalation treat-to-target randomized controlled trial to study the effect of baseline kidney function on safety and efficacy of allopurinol dose escalation to achieve serum urate (SU) <6 mg/dl.

In a trial of 183 gout patients, patients were randomized to either immediate or delayed (by 12 months) allopurinol dose escalation until serum uric acid (SUA) was <6 mg/dl. The effect of baseline kidney function on urate lowering and adverse effects was investigated.

Regardless of baseline creatinine clearance (CrCL) (<30 ml/min;  ≥30 to <60 ml/min; or ≥60 ml/min), the percentage who achieved SUA <6 mg/dl at the final visit was similar, 64.3% vs. 76.4% vs. 75.0%, respectively (p = 0.65).

The mean allopurinol dose at month 24 was significantly lower in those with CrCL <30 ml/min as compared to those with CrCL ≥30 to <60 ml/min or CrCL ≥60 ml/min (250 mg; 365 mg; 460 mg/day, respectively (p < 0.001). Thus, higher doses were needed to achieve target SUA levels in those with normal function and lower doses were needed with renal impairment.

Adverse events (deaths, increased LFTs, change in renal function) were similar among groups.

Allopurinol dose escalation to target SU appears to be safe in people with severe CKD. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Ironwood Retreats from the US Gout Market

Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019. In addition the Duzallo and Zurampic Patient Savings Program were also discontinued on December 31, 2018.

The company stated that this was a financial decision unrelated to the efficacy or safety of lesinurad.

Allopurinol Reduces Cardiovascular Outcomes in Diabetes

A Canadian study has shown that elderly diabetics who take allopurinol have a significant reduction in cardiovascular outcomes.  

Hyperuricemia has been shown to be a biomarker for cardiovascular outcomes in multiple disorders. These investigators studied the effect of allopurinol and mortality on CV outcomes in a population-based retrospective cohort study from Ontario, Canada.

FDA Slaps a Boxed Warning on Febuxostat for CV Risk

The U.S. Food and Drug Administration (FDA) has reviewed data from the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial and concluded there is an increased risk of death with Uloric (febuxostat) compared with allopurinol, and has added this as a boxed warning to the drug’s product label.

U.S. Gout Rates Remain Steady, but Substantial

Using data from 5,467 adults in the US in the National Health and Nutrition Examination Survey (NHANES) for the years 2007-2016, researchers found that the prevalence of gout and hyperuricemia has remained at 3.9%, having doubled from the 1960s to the 1990s, corresponding to an estimated 9.2 million adults with gout in 2015-2016.

Febuxostat Gets Reprieve from FDA Advisory Panel

On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) study. 

The Vote